Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2023 Earnings Call Transcript
Operator: Good morning. And welcome to Cellectar Biosciences 2023 Yearend Earnings Call. Today's call is being recorded.
Source: insidermonkey.com
Marginal Zone News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Marginal Zone. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Marginal Zone Today - Breaking & Trending Today
Velcade and Rituxan Help Improve Responses in Marginal Zone Lymphoma
A treatment combination that includes Velcade and Rituxan helps improve responses and the safety profile in marginal zone lymphoma, according to a phase 2 trial.
Source: curetoday.com
Completion of Sampling Program at River Valley PGE Project
Class 1 Nickel and Technologies Ltd. has announced the conclusion of the sample collection component of an exploration program that included 287 B-horizon soil geochemical sampling and 287 biogeochemical plant sampling at its River Valley PGE Project, which is situated about 100 road-km east of Sudbury, Ontario, Canada.
Source: azomining.com
Class 1 Nickel Completes Geochemical Soil and Biogeochemical Sampling Program at its River Valley PGE Project, near Sudbury, Ontario
TORONTO, June 26, 2023 (GLOBE NEWSWIRE) -- Class 1 Nickel and Technologies Ltd. (CSE: NICO/OTCQB: NICLF) (
Source: marketscreener.com
BeiGene: BRUKINSA (zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) in Great Britain by MHRA
MHRA marketing authorizations follow recent European Commission marketing authorizations BRUKINSA is the only treatment authorized for MZL in Great Britain BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE:
Source: finanznachrichten.de